Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy

Journal of Hospital Infection

Volumn 85, Issue 1, 2013, Pages 28-32

  Jardin, C G M ^a   Palmer, H R ^a   Shah, D N ^a,b   Le, F ^a   Beyda, N D ^a,b   Jiang, Z ^c   Garey, K W ^a,b,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic stewardship; Clostridium difficile; Cohort study; Disease severity; Metronidazole; Oral vancomycin

Indexed keywords

BACTERIAL TOXIN; METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CAUCASIAN; CHARLSON COMORBIDITY INDEX; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PSEUDOMEMBRANOUS COLITIS; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

EID: 84881669744     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2013.04.017     Document Type: Article

References (25)

1. Hall A.J., Curns A.T., McDonald L.C., Parashar U.D., Lopman B.A. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012, 55:216-223.
2. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
3. Lucado J., Gould C., Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009 2012, HCUP Statistical Brief #124, Agency for Healthcare Research and Quality, Rockville, MD.
4. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
5. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
6. Muto C.A., Pokrywka M., Shutt K., et al. Alarge outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
7. Salazar M., Baskin L., Garey K.W., DuPont H.L. Clostridium difficile-related death rates in Texas 1999-2005. JInfect 2009, 59:303-307.
8. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
9. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
10. Louie T, Gerdsom M, Grimard D, etal. Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium difficile associated diarrhea (CDI). Abstract presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 17-20 September 2007.
11. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
12. Le F., Arora V., Shah D.N., Salazar M., Palmer H.R., Garey K.W. Areal-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy 2012, 32:129-134.
13. Barbut F., Kajzer C., Planas N., Petit J.C. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. JClin Microbiol 1993, 31:963-967.
14. Garey K.W., Jiang Z.D., Ghantoji S., Tam V.H., Arora V., Dupont H.L. Acommon polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010, 51:1406-1410.
15. Palmer H.R., Weston J., Gentry L., et al. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm 2011, 68:2170-2174.
16. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40:373-383.
17. Horn S.D., Sharkey P.D., Bertram D.A. Measuring severity of illness: homogeneous case mix groups. Med Care 1983, 21:14-30.
18. Jiang Z.D., DuPont H.L., La Rocco M., Garey K.W. Invitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. JClin Pathol 2010, 63:355-358.
19. Gumerlock P.H., Tang Y.J., Meyers F.J., Silva J. Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces. Rev Infect Dis 1991, 13:1053-1060.
20. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000, 186:307-312.
21. Lemee L., Bourgeois I., Ruffin E., Collignon A., Lemeland J.F., Pons J.L. Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 2005, 151:3171-3180.
22. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
23. Al-Nassir W.N., Sethi A.K., Nerandzic M.M., Bobulsky G.S., Jump R.L., Donskey C.J. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008, 47:56-62.
24. Berwick D.M. Disseminating innovations in health care. JAMA 2003, 289:1969-1975.
25. Al-Nassir W.N., Sethi A.K., Li Y., Pultz M.J., Riggs M.M., Donskey C.J. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.